Key result
Platelet reactivity measured by LTA and VerifyNow significantly discriminated the risk of 30-day ischemic events (15.8% overall rate) after PCI (all p<0.001), whereas MEA did not (p>0.05).
Why the study?
Do different platelet function tests (LTA, VerifyNow, MEA) predict 30-day ischemic events in Korean patients receiving clopidogrel prior to PCI?
Population
n=228 Korean patients receiving clopidogrel prior to undergoing percutaneous coronary intervention (PCI)
Design
Cohort
Follow-up
30-day
Authors
Loading...
LTA and VerifyNow may aid 30-day risk stratification after PCI in East Asians on clopidogrel; leaves open whether MEA or routine testing should change practice.
Observational (n=228)
Do different platelet function tests (LTA, VerifyNow, MEA) predict 30-day ischemic events in Korean patients receiving clopidogrel prior to PCI?
LTA and VerifyNow assays, but not MEA, effectively discriminate the risk of 30-day ischemic events after PCI in East Asian patients on clopidogrel, with predictive cut-offs depending on sampling time.
Zhang et al. (2013) conducted an observational in Patients undergoing PCI (n=228). Platelet function measurement assays (LTA, VerifyNow, MEA) was evaluated on 30-day occurrence of ischemic events after PCI. Platelet reactivity measured by LTA and VerifyNow significantly discriminated the risk of 30-day ischemic events (15.8% overall rate) after PCI (all p<0.001), whereas MEA did not (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: